ESR1 and breast cancer: This enrichment was stronger in the ER+ MCF7 and T47D cell lines as compared to available ER− breast cancer, normal breast, and other non-breast cell lines (Fig. 2c, Additional file 1: Figure S2b, and Additional file 2: Table S4), consistent with an additional layer of ER-mediated cell-type specificity [27].